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Summary Two colorectal (HT29, LoVo) and one gastric (MKN45) human tumour cell lines were examined
for their in vitro trophic response to human gastrin-17. MKN45 and HT29 responded by increased 75Se-
selenomethionine uptake to exogenous gastrin (139+5.5% and 123+3% of control values respectively)
whereas LoVo showed no significant response to this hormone. When these same cell lines were grown as
xenografts in nude mice, similar responses were seen to exogenously administered human gastrin-17
(10jigmouse' day-1, subcutaneous injection). MKN45 xenografts showed a greater response to continuously
administered gastrin (osmotic mini-pumps, (10jgmouse-Ilday-) when compared to the same dose given via
a subcutaneous bolus injection. The hormone-treated xenografts had a two-fold increase in tumour cross-
sectional area and growth rate when compared to saline-treated controls. Dose-response studies revealed that
0.4 g gastrinmouse- day-l appeared to be the minimally effective dose. As gastric and colorectal tumour
cells show a trophic response to gastrin, antagonists of the gastrin receptor may prevent this effect causing
tumour stasis. The gastric tumour cell line, MKN45, is gastrin-responsive and would be an ideal model for
screening potent receptor antagonists.
The hormonal control of breast and prostatic tumours has
become well established (Carter et al., 1977; Higgins &
Hodges, 1941) and clinically effective hormone antagonists
such as tamoxifen are widely used.
Gastrointestinal (GI) tract tumours are among the com-
monest found in humans (UK data: colon and rectum,
25,000; stomach 11,000 cancer deaths per year). Radio-
therapy and cytotoxic drug therapy have failed to produce
significant therapeutic results. An investigation into the
hormonal control of such tumours with a view to developing
antagonists of hormone action may yield alternative modes
of treatment for gut tumours.
Gastrin appears to be an important trophic hormone for
both normal and malignant GI mucosal cells. Gastric and
duodenal mucosal cells were shown to respond to penta-
gastrin when cultured in vitro (Miller et al., 1973;
Lichtenberger et al., 1973). Naturally occurring gastrins
(G171, G1711, G3411) were several times more potent than
pentagastrin in their trophic effects on normal mucosa
(Johnson, 1977). More recently it was shown that the density
of fundic mucosal endocrine cells was positively related to
levels of serum gastrin (Borch et al., 1986).
GI tract tumour cells have been shown to respond to
gastrin. Both established colorectal cell lines (Kusyk et al.,
1986; McRae et al., 1986) and gastric cell lines (Watson et
al., 1988) respond to gastrin in vitro. The same has been
shown with gastric and colorectal primary tumour cells
(Moyer, 1983; Sirinek et al., 1985).
The need to produce gastrin (receptor) antagonists and
test them in reliable in vitro and in vivo systems is fundamen-
tal to determining the possible role of such agents in the
treatment of GI cancer. This paper compares the gastrin
responsiveness of human gastric and colorectal cell lines in
vitro and in vivo.
Materials and methods
Established cell lines
Three established human gastric and colorectal cell lines
were examined for gastrin-dependence: (i) MKN45 is a
human adenocarcinoma cell line originally derived from a
metastatic tumour of the liver from a 62-year-old Japanese
woman with an undifferentiated adenocarcinoma of the
stomach (Hojo, 1977); (ii) HT29 and LoVo are human
colorectal adenocarcinoma cell lines.
The cells used for in vitro assays had previously been
grown in immunocompromised (nude) mice (Olac, Oxford-
shire) and had been passaged less than five times in vitro, as
previously described (Watson et al., 1988). The cells were
grown in vitro in Dulbecco's growth medium (DMEM)
supplemented with 10% fetal calf serum (FCS, Gibco) at
37°C in the presence of 5% CO2.
In vitro assessment of cell growth in the presence ofgastrin
Cells were synchronised in the GI phase of cell growth by
the addition of excess thymidine and cell growth was
assessed by 75Se-selenomethionine incorporation as pre-
viously described (Watson et al., 1988). Human gastrin-17
(G17, Sigma, Dorset) concentrations between 0.02 and
l.O,g1- l were used.
Growth of cell lines as xenografts in nude mice
Xenografts were initiated by injection of cell lines as pre-
viously described (Watson et al., 1988). The resultant
tumours were aseptically dissected, mechanically minced and
5mm3 pieces of tumour tissue transplanted into the animals
and randomised into experimental groups. The control
groups of animals received phosphate-buffered saline (PBS)
either by a subcutaneous bolus injection (0.2ml) daily or by
continuous infusion with the use of 14 day osmotic mini-
pumps (Alzet, London, model 2002). Gastrin-treated animals
received G17 either subcutaneously (single dose,
10jgmouse-1day-', 0.2ml) or by 14 day mini-pump (0.4,
2.0, 10.0pgmouse- day-1).
Tumour growth was evident from between days 4 and 7.
The tumours were measured two or three times a week, with
the use of calipers, for 3 weeks and the measurements were
made by an independent observer. The two largest perpendi-
cular diameters of the tumours were measured and from
these the cross-sectional areas were derived.
Measurements of serum gastrin levels after administration of
gastrin
Nude mice were starved overnight and then tail bled to
measure fasting serum gastrin levels.
Aliquots of 200,u1 blood were removed per mouse at each
tail bleed, which yielded 20p1 serum. The gastrin levels of
the serum were then assayed using a Radioimmunoassay kit
(CIS Labs, UK) with the detection limit being 15 pgml-1.
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Statistics
Statistical analysis on both in vitro and in vivo data was
performed by using the paired Student's t test and the term
'% of control' used to compare data is defined as
c.p.m. in presence ofgastrin
c.p.m. in absence ofgastrin
In vivo data were also subjected to a one-way analysis of
variance which was performed over the complete time scale
of each experiment. Where replicates were performed, the
standard error of the mean was calculated.
Results
The cell lines examined for their gastrin dependence had
been passaged less than five times in vitro as the growth
response of tumour cells to gastrin may be lost on prolonged
in vitro passage (Watson et al., 1988).
Figure 1 shows a typical experiment in which the gastric
cell line, MKN45 and the colorectal cell line, HT29 both
incorporated 75Se-selenomethionine to greater levels in the
presence of G-17. Maximum responses of 139+5.5%
(MKN45) and 123+3% (HT29) of control values were
achieved at gastrin concentrations of 0.2 and 1.0pg1-1
respectively (Figure 1). The colorectal cell line, LoVo, failed
to achieve a significant response to G17.
The same cell lines were grown as xenografts in nude
mice. In all xenograft experiments, an arbitrary tumour area
of 1.5cm2 has been designated to indicate satisfactory
tumour growth from transplanted tissue. With MKN45
xenografts (Figure 2a) 1/9 of PBS-treated mice achieved a
tumour cross-sectional area greater than 1.5cm2 whereas
4/10 gastrin treated mice had tumours of such a size. The
mean growth rates of PBS-treated and gastrin-treated xeno-
grafts were 54+8 mm2 day-1 and 68 +11 mm2 day-1 respec-
tively. Statistical analysis revealed no significant difference
between the two groups.
The growth of LoVo xenografts was not influenced by
administration of gastrin (Figure 2b). HT29 xenografts had a
greater mean growth rate in the absence of gastrin
(133 +21 mm2 day-1) when compared to MKN45
(54+8mm2day-) and LoVo (54+9mm2day-1) (P<0.01).
In the PBS-treated animal group, 3/4 HT29 xenografts
achieved a tumour size greater than 1.5cm2 compared to 5/5
in the gastrin-treated group, which had a mean growth rate
of 147+ 12mm2day-1. These differences, however, were not
significant.
To try and develop a more gastrin-responsive xenograft
line, the four MKN45 xenografts achieving an area of
greater than 1.5cm2 in the gastrin-treated group (Figure 2a)
were removed, the tissue was combined and retransplanted
into two more groups of experimental animals. These were
randomised into PBS and gastrin-treated (10pgmouse-1
day-1) groups. From Figure 3, it can be seen that 3/10 PBS-
treated mice had xenografts greater than 1.5cm2 compared
to 7/10 gastrin-treated animals. This was found to be
statistically significant (one way analysis of variance,
P<0.01). The mean growth rate of PBS-treated xenografts
was 68 +9mm2 day -1 compared to 90+9mm2 day -1 in the
gastrin treated tumours.
As human gastrin-17 has a short half-life in the circulation
(6min; Walsh & Grossman, 1975), it was decided to admin-
ister the hormone by continuous infusion with the use of an
osmotic mini-pump. Gastrin-17 was delivered over a 14 day
period from the day of xenograft transplantation. Figure 4
shows the growth response of both MKN45 and HT29
xenografts to pumped gastrin. The growth rate of MKN45
xenografts in response to gastrin (10pgmouse-'day-1) was
178+20mm2day-I compared to 94+9mm2day-I in the
PBS treated controls (P<0.01, Student's t test, P<0.01, one-
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Figure 1 The growth response to G17 of established human
gastric (a) (MKN45) and colorectal; (b) HT29; (c) LoVo cell
lines. Points, means of triplicate samples, *P<0.000l, **P<0.01.
Student's t test.
The growth rate of HT29 xenografts in response to
constantly infused gastrin was 148 +21 mm2 day-1 compared
to 105 + 15mm2day-1, in the PBS-treated controls. There
was a trend to increased growth in the presence of gastrin
which was not significant.
A titration was performed on the growth response of
MKN45 xenografts to pumped gastrin. Gastrin was adminis-
tered at decreasing concentrations of 10.0, 2.0 and
0.4pgmouse-1day-I and the growth of the corresponding
xenografts was measured over a 24-day period (Figure 5).
For comparative purposes, the mean of the tumour measure-
ments for each group was calculated.
By day 19, animals treated with the two higher gastrin
concentrations had xenografts of greater size than the
control animals (10pgmouse-I day-1; P<0.05,
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Figure 3 The growth of gastrin-responsive MKN45 xenografts
in nude mice: response to subcutaneously administered gastrin.
Individual tumour measurements: i, PBS control 0; ii, gastrin-
treated 0 (l0pgmouse- day-1). *P<O.O1, one-way analysis of
variance.
Time (days)
Figure 2 The growth response of human gastric (a) (MKN45)
and colorectal; (b) HT29; (c) LoVo tumour xenografts to
subcutaneously administered gastrin (10 pg mouse - day 1). Indi-
vidual tumour measurements: i, PBS control 0; ii, gastrin-
treated 0.
2pg mouse-1 day-1; P<0.01). At day 21 the xenografts of
mice treated with all three gastrin concentrations (10, 2,
0.4,pg mouse-1 day-') were significantly greater than the
control (P<0.05, P<0.01, P<0.05 respectively). By day 24,
xenografts of animals treated with the lower gastrin
concentrations were not significantly different from the
control, whilst xenografts of animals treated with 10 and
2pg mouse- 1 day- 1 remained so (P<0.05, P<0.01).
Measurements of fasting serum gastrin levels were taken
during each dose of administered gastrin. In PBS-treated
animals a mean fasting serum gastrin concentration of
134+34pgml-1 was achieved whereas with pumped gastrin
at 10, 2 and 0.4Mg mouse -1day-1, mean fasting serum
gastrin levels of 307+ 100, 181 +45 and 155 +34pgml1 were
achieved (n = 5).
Discussion
As radiotherapy and chemotherapy of GI tumours have
failed to produce beneficial therapeutic results an alternative
mode of treatment has been sought. This study investigates
the hormonal control of such tumours with a view to
developing antagonists, if tumour growth shows hormonal
dependence.
Early results showed that GI tract tumour cells have a low
growth response to gastrin after long-term in vitro growth
(Watson et al., 1988). However, if the same cells were grown
as xenografts in nude mice and re-examined after short-term
in vitro growth, they showed an elevated response.
In the present study, MKN45 and HT29 cells incorporated
elevated levels of 75Se-selenomethionine in the presence of
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Figure 4 The growth response of MKN45 (a) and HT29 (b)
xenografts to gastrin administered by continuous infusion (via an
osmotic mini-pump, 10,igmouse-1 day-1). Individual tumour
measurements: i, PBS control 0; ii, gastrin treated 0. *P<0.01,
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Figure 5 The dose-response of MKN45 xenografts to gastrin
administered via an osmotic mini-pump. Mean tumour measure-
ments (n=5), PBS control LI, gastrin (pgmouse'day'1) 0.4 ~,
2.0 EL 10.0 S.
These same cell lines, grown as xenografts in nude mice,
did not respond significantly to daily subcutaneous injections
of human G-17. This is not surprising as the tumour cells
will only be exposed to the hormone for a short time, as the
serum half-life of G-17 is 6min (Walsh & Grossman, 1975).
However, when MKN45 xenografts were exposed to conti-
nuously administered gastrin it induced a two-fold increase
in cross-sectional area and mean rate of tumour growth
when compared to saline-treated controls. HT29 xenografts
showed a trend to increased growth in the presence of
continuously infused gastrin that was not statistically
significant.
In the MKN45 xenograft model, pumped gastrin which
induced up to three fold increases in circulating fasting
serum gastrin levels (when compared to PBS-treated animals)
appeared to increase the growth of the tumours in the short-
term. In accord with this, studies in humans have revealed
that fasting serum gastrin levels are elevated 8.5-fold in
patients with colorectal cancer (Smith et al., 1987) and 3.5-
fold in patients with carcinoma of the stomach (McGuigan
& Trudeau, 1973).
A similar study was performed with xenotransplanted
human gastric and colon carcinomas (Sumiyoshi et al.,
(1984). A human gastric carcinoma, SC-6-JCK, responded
trophically to gastrin whereas a second human gastric carci-
noma, ST15, and a colonic adenocarcinoma, Co3, failed to
respond. However, the response with SC-6-JCK was
obtained with pentagastrin (10pgmouse-Iday- 1) which is
known to be less potent at promoting a trophic response
with normal cells than gastrin-17 (Johnson, 1977) and has
been shown to have a lower binding affinity for the gastrin
receptor when compared to gastrin-17 (P. Singh, personal
communication). The pentagastrin was also administered via
a single subcutaneous injection. It is possible therefore that
SC-6-JCK may have greater sensitivity to the action of
gastrin than MKN45.
A recent study has shown that a mouse colon adeno-
carcinoma cell line, MC26, responded to pentagastrin (3.25-
15.00pgmouse-1 day-1) administered by intraperitoneal
injections (Winsett et al., 1986). It has also been found that
both exogenous gastrin (pentagastrin, 2mgkg-1, subcuta-
neous injection) and endogenous hypergastrinaemia (induced
by antral exclusion) exerted trophic effects on chemically
induced colorectal neoplasms in the rat (McGregor et al.,
1982). The lack of gastrin response seen in the human
colorectal tumour cells examined in the present study may be
dose related and further experiments will be performed to
investigate this.
In conclusion, we have demonstrated that a human gastric
adenocarcinoma cell line, MKN45, when initiated as a
xenograft in nude mice, almost doubles in size upon contin-
uous administration of human G-17. Together with the cell
line's gastrin responsiveness in vitro it is an ideal candidate
for screening gastrin (receptor) antagonists with a view to
examining them as potential therapeutic agents.
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